


Supplemental Figure 2



Supplemental Figure 2 | Supplemental flow plots

a Proportion of CD45⁺CD4⁺Foxp3⁺ T cells, CD45⁺CD4⁺Foxp3⁺ Tregs, CD45⁺CD3⁺CD8⁺ T cells, CD45⁺F4/80⁺Ly-6G⁺CD11c⁺ cells, or CD45⁺CD11b⁺Gr-1⁺ cells from LY2 or MOC2 tumors harvested 4 or 3 days post-RT, respectively, compared to 0 Gy controls (n=3 mice/group). **b** Proportion of CD45⁺CD3⁺CD4⁺Foxp3⁺CD44^{hi}CD62L^{lo} T cells or CD45⁺CD3⁺CD8⁺CD44^{hi}CD62L^{lo} T cells from LY2 or MOC2 tumors harvested 4 or 3 days post-RT, respectively, compared to 0 Gy controls (n=3 mice/group). **c** Proportion of CD45⁺CD3⁺CD4⁺Foxp3⁺ T cells or CD45⁺CD3⁺CD8⁺ T cells in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **d** Proportion of CD45⁺CD3⁺CD4⁺Foxp3⁺ T cells or CD45⁺CD3⁺CD8⁺ T cells in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **e** Proportion of CD45⁺CD3⁺CD4⁺Foxp3⁺ T cells expressing IFNγ or TNFα in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **f** Proportion of CD45⁺CD3⁺CD8⁺ T cells expressing IFNγ or TNFα in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **g** Proportion

of CD45⁺CD3⁺CD4⁺Foxp3⁻ T cells expressing IFN γ or TNF α in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **h** Proportion of CD45⁺CD3⁺CD8⁺ T cells expressing IFN γ or TNF α in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).